Skip to main content
SpringerLink
Log in

Authors’ Reply to Alain Braillon’s Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 08 August 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Braillon A. Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”. Drug Saf. 2016. doi:10.1007/s40264-016-0447-4

  2. Sinclair JM, Chambers SE, Shiles CJ, Baldwin DS. Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf. 2016;39(7):627–45.

    Article  CAS  PubMed  Google Scholar 

  3. Haynes B, Haines A. Barriers and bridges to evidence based clinical practice. BMJ. 1998;317(7153):273–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mann K, Bladstroem A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–13.

    Article  CAS  PubMed  Google Scholar 

  5. Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432–42.

    Article  CAS  PubMed  Google Scholar 

  6. van den Brink W, Aubin H-J, Bladstrom A, et al. Efficacy of as-needed nalmefene in alcohol dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomised controlled 6-month studies. Alcohol Alcoholism. 2013;48(5):570–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. van den Brink W, Mann K, Gual A, Aubin H-J. Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency. BMJ. 2014;348:g2017.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

    Julia M. A. Sinclair, Sophia E. Chambers & David S. Baldwin

  2. University of Cape Town, Cape Town, South Africa

    David S. Baldwin

  3. University Department of Psychiatry, Academic Centre, College Keep, 4-12 Terminus Terrace, Southampton, SO14 3DT, UK

    Julia M. A. Sinclair

Authors
  1. Julia M. A. Sinclair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophia E. Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David S. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia M. A. Sinclair.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this letter.

Conflict of interest

Within the last 3 years, David S. Baldwin has received two grants from Lundbeck A/S for research on an antidepressant compound and has participated in advisory board meetings for this. Julia M.A. Sinclair has participated in an advisory board for Lundbeck A/S for nalmefene and received speaker fees. She is the joint clinical lead for the Alcohol Programme for the Wessex Academic Health Science Network. Sophia E. Chambers has a studentship funded by the Wessex Academic Health Science Network and Lundbeck partnership.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sinclair, J.M.A., Chambers, S.E. & Baldwin, D.S. Authors’ Reply to Alain Braillon’s Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”. Drug Saf 39, 1153–1154 (2016). https://doi.org/10.1007/s40264-016-0448-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-016-0448-3

Keywords

Search

Navigation